SKorea Hopes New Speed Train Links Will Help Boost Birthrate

A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)
A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)
TT

SKorea Hopes New Speed Train Links Will Help Boost Birthrate

A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)
A woman walks as the skyline is covered with a thick haze caused by yellow dust at a park in Goyang, South Korea, Friday, March 29, 2024. (AP Photo/Ahn Young-joon)

South Korea is launching a high-speed train service that will reduce the travel time between central Seoul and its outskirts, a project officials hope will encourage more youth to consider homes outside the city, and start having babies, Reuters reported.
South Korea has the world's lowest fertility rate, and its youth have often cited long commutes and cramped, expensive housing in greater Seoul, home to about half the population, as the main reasons for not getting married and starting a family.
The birth rate in Seoul is even lower than the national average, and the government has tried to boost the number of newborns through subsidies, with little success.
Officials are now pinning their hopes on the Great Train eXpress (GTX), a 134 trillion won ($99.5 billion) underground speedtrain project that, by 2035, will provide six lines linking Seoul to several outlying areas.
On Friday, President Yoon Suk Yeol inaugurated a section of the first line, which will cut the commute time from Suseo in capital to the satellite city of Dongtan to 19 minutes from 80 minutes now on a bus.
The shorter commute "will enable people to spend more time with their family in the mornings and evenings," he added.
The line is due to go into service on Saturday, and once fully operational, the GTX will be one of the fastest underground systems in the world, with trains travelling at speeds of up to 180 km per hour (112 mph), officials said.
Owning a home in South Korea is costly, with median prices hitting a peak in June 2021 after rising 45% over five years. Seoul is particularly expensive, offering some of the worst value for money per square foot of any advanced economy, analysts say.
Land Minister Park Sang-woo told Reuters the GTX would allow young people to consider homes far away from the capital without having to spend hours commuting. The time they get back can go towards their families, he added.
"With two-hour commute on the way home, for example, how can anyone make time for babies? The idea is to give people more leisure time after work," he said.
Some analysts, however, said the GTX could contribute to the decline of rural South Korea, by sucking more people into the already overcrowded capital.
"To revive regional towns facing extinction, the most important thing is to equip other areas with a similar kind of public infrastructure too," said Kim Jin-yoo, professor of Urban Planning & Transportation Engineering at Kyonggi University.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”